Apparently sales were so abysmal for Pfizer’s insulin inhaler known as Exubera that the drug giant, manufacturer of bestselling pill Viagra, has killed it. Patients only spent a droopy $12 million on the oddly-named Exubera last year. The world just isn’t ready for insulin without needles, and besides there were complaints that the Exubera inhalers looked like bongs. The consumer medtech market can be so harsh! Maybe if the insulin bongs streamed RSS feeds or could double as Wii controllers, the public would have spent a hundred million more.
Pfizer Gives Last Rites to Exubera [via WSJ]
